| Name | Title | Contact Details |
|---|
Southwest Center is a leader in providing HIV/AIDS services in Phoenix, AZ, including: HIV and STD testing, LGBTQ-friendly medical care, PrEP & PEP, community outreach, case management, behavioral health, empowerment programs, nutrition servic...
ION Medical is a Mission Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Established in 1946, OMRF is an independent, nonprofit biomedical research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders, and diseases of aging. Breakthroughs in our labs have led to three FDA-approved drugs, including the first targeted therapy approved in the U.S. for sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. OMRF`s critical research is helping people live longer, healthier lives, one discovery at a time. Along the way, OMRF has garnered worldwide media attention, from leading scientific publications like The New England Journal of Medicine and Science to The New York Times and The Wall Street Journal. By pushing the boundaries of biomedical science, our researchers are helping to win the war against human disease, one discovery at a time.
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.